Argus lines up United Therapeutics (UTHR -1.4%) as an undervalued name in the healthcare sector,...

|About: United Therapeutics Corpo... (UTHR)|By:, SA News Editor

Argus lines up United Therapeutics (UTHR -1.4%) as an undervalued name in the healthcare sector, as it maintains a Buy rating on the biotech concern. Analysts with the firm expect Argus to hit its 2012 sales target, as they raise their price target on shares by $8 to $60.